[{"id":"06664c3b-1c85-4e03-93c9-1672ab005d48","acronym":"ORIN1001-C1","url":"https://clinicaltrials.gov/study/NCT05154201","created_at":"2021-12-13T14:12:30.912Z","updated_at":"2024-07-02T16:35:14.161Z","phase":"Phase 1/2","brief_title":"Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.","source_id_and_acronym":"NCT05154201 - ORIN1001-C1","lead_sponsor":"Orinove, Inc.","biomarkers":" HER-2 • ER • PGR • ERN1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR • ERN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ORIN1001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-03-19"},{"id":"c793b73e-238c-4a86-b184-43cb1d84cb73","acronym":"","url":"https://clinicaltrials.gov/study/NCT03615391","created_at":"2021-01-18T17:46:01.138Z","updated_at":"2024-07-02T16:37:08.318Z","phase":"","brief_title":"Predictive Role and HuR Mechanisms of Regulation in the Brain Tumours","source_id_and_acronym":"NCT03615391","lead_sponsor":"Central Hospital, Nancy, France","biomarkers":" BCL2 • CCND1 • VEGFA • HIF1A • CASP3 • ATF6 • ERN1 • MIR16 • SIRT1 • MCM6","pipe":"","alterations":" ","tags":["BCL2 • CCND1 • VEGFA • HIF1A • CASP3 • ATF6 • ERN1 • MIR16 • SIRT1 • MCM6"],"overall_status":"Unknown status","enrollment":" Enrollment 140","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2018-08-03"}]